360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

Cellectis SA

Type: Company

Name: Cellectis SA

Fact Sheet: Fact Sheet for Cellectis SA

First reported 4 hours ago - Updated 4 hours ago - 1 reports

Iowa State University

Cellectis Secures 2 Patents for TAL-effector nuclease

Cellectis, a global genome engineering specialist, announced the issuance by the USPTO on May 14th, of two new US patents (US 8,440,431 and US 8,440,432) directed to TAL-effector nucleases. As a company focusing in the genome engineering industry, the ... [Published Individual.com - 4 hours ago]

Entities: Cellectis SA, Nuclease, Genome, Iowa State University, University of Minnesota

First reported 22 hours ago - Updated 22 hours ago - 1 reports

Cell Therapy Catapult appoints CSO

Professor Johan Hyllner The , which is focused on the development of the UK cell therapy industry, has appointed Professor Johan Hyllner to its executive management team as Chief Scientific Officer (CSO). He joins from French company Cellectis, where ... [Published Manufacturing Chemist - 22 hours ago]

Entities: Cell Therapy, Cellectis SA, Appointed

First reported May 17 2013 - Updated May 17 2013 - 1 reports

United States District Court

Precision BioSciences wins patent infringement lawsuit against Cellectis

Precision BioSciences, Inc., a genome engineering technology company, has won a patent infringement lawsuit against Cellectis SA, a biotechnology company. A jury in the US District Court for the District of Delaware found that all of the claims of Cellectis' ... [Published Individual.com - May 17 2013]

Entities: Cellectis SA, Precision Biosciences Inc, Patent Infringement, United States District Court, Lawsuit

First reported May 16 2013 - Updated May 16 2013 - 2 reports

United States Patent And Trademark Office

Cellectis: TAL-effector Nuclease: Issuance by the USPTO of Two New Patents

NEW BRIGHTON, Minn.--(BUSINESS WIRE)--Regulatory News: Cellectis (Paris:ALCLS) (NYSE PA: ALCLS), the global genome engineering specialist, announced the issuance by the USPTO on May 14th, 2013 of two new US patents (US 8,440,431 and US 8,440,432) directed ... [Published BioSpace - May 16 2013]

Entities: Nuclease, Cellectis SA, United States Patent And Trademark Office

First reported May 10 2013 - Updated May 11 2013 - 2 reports

Jury finds Cellectis meganuclease claims invalid, but infringed by Precision Biosciences under Doctrine of Equivalents

| Holman's Biotech IP BlogHome » Blogs » As reported in an earlier post, on March 1, 2011, Cellectis sued Precision Biosciences in the District Court of Delaware [CIV-No.-11-173] for allegedly infringing US patent number 7,897,372, directed to "I-CreI ... [Published BioPortfolio - May 11 2013]

Entities: Precision Biosciences Inc, Doctrine of Equivalents, Cellectis SA

First reported May 06 2013 - Updated May 06 2013 - 3 reports

Precision BioSciences Wins Patent Infringement Lawsuit Against Cellectis

Staying up-to-date has never been simpler. Sign up for the today! RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc., a leader in the field of genome engineering, today announced that it has won a patent infringement lawsuit against ... [Published BioSpace - May 06 2013]

Entities: Precision Biosciences Inc, Cellectis SA, Patent Infringement

First reported May 06 2013 - Updated May 06 2013 - 1 reports

Cellectis Posts 2012 financial results

Cellectis, a global genome engineering specialist, presented its consolidated financial statements for the 2012 fiscal year, approved for publication by the Board of Directors at their meeting. In a release on April 29, the company noted financial results ... [Published Individual.com - May 06 2013]

Entities: Cellectis SA, Regenerative Medicine, Genome, Therapeutics, T-cells

First reported May 02 2013 - Updated May 02 2013 - 1 reports

David Sourdive, Vice President of Corporate Development at Cellectis, has been appointed by French Foreign Trade Ministe

Cellectis (Alternext: ALCLS), the French genome engineering specialist, has announced the appointment of David Sourdive as head of the Treat Yourself Better initiative. This project aims to make France more competitive in the health sector. To this end, ... [Published NewsBlaze - May 02 2013]

Entities: Cellectis SA, Nicole Bricq, Appointed

First reported Apr 22 2013 - Updated Apr 22 2013 - 1 reports

Cellectis Bioresearch Rolls Out VizuCELL Cell Lines for Live Cell Imaging

Cellectis bioresearch, a subsidiary of Cellectis Group, a genome engineering specialist, announced the launch of VizuCELL cell lines, a tool for live cell imaging.According to a release, as live cell imaging has become a requisite analytical tool in most ... [Published Zecco - Apr 22 2013]

Entities: Cellectis SA, Cell Lines, Genome, Cytoskeleton

First reported Apr 18 2013 - Updated Apr 18 2013 - 1 reports

Cellectis develops VizuCELL cell lines for biomedical research, cell biology

Cellectis bioresearch, a subsidiary of Cellectis, has developed VizuCELL cell lines for biomedical research and cell biology. ... [Published PBR - News - Apr 18 2013]

Entities: Cellectis SA, Cell Lines

First reported Mar 09 2013 - Updated Mar 09 2013 - 1 reports

Cellectis inks pact with Stemgent to provide custom genome-engineered iPS cells

Cellectis bioresearch, a subsidiary of Cellectis Group, the genome engineering specialist, has signed a collaboration agreement with Stemgent, Inc. to provide research services that combines mRNA reprogramming technology and genome engineering.The partnership ... [Published PharmaBiz - Mar 09 2013]

Entities: Cellectis SA, Stemgent Inc, Genome, Regenerative Medicine, mutations

First reported Mar 08 2013 - Updated Mar 08 2013 - 1 reports

Cellectis, Stemgent to provide Genome-engineered iPS Cells

Cellectis bioresearch, a subsidiary of Cellectis Group, has signed a collaboration agreement with Stemgent to provide research services, which combine mRNA reprogramming technology and genome engineering. ... [Published PBR - News - Mar 08 2013]

Entities: Cellectis SA, Stemgent Inc, Messenger RNA, Genome

Quotes

Pr. Daniel Voytas said that "thanks to its technology, Cellectis develops easy and ready-to-use tools for genome customization enabling the engineering of cells with optimized features for drug discovery, gene function studies and industrial biotechnology."

Cellectis Secures 2 Patents for TAL-effector nuclease [Published Individual.com - 4 hours ago]

...verdict represents a fantastic victory for the Precision BioSciences team and all of our partners," said Precision BioSciences CEO Matthew Kane. "We will continue to seek to work collaboratively with all members of the biotechnology industry, but we hope this decision underscores that we will defend ourselves vigorously and effectively."

Precision BioSciences wins patent infringement lawsuit against Cellectis [Published Individual.com - May 17 2013]

More From BioPortfolio on "Jury finds Cellectis meganuclease claims invalid, but infringed by Precision Biosciences under Doctrine of Equivalents"

Jury finds Cellectis meganuclease claims invalid, but infringed by Precision Biosciences under Do ... [Published BioPortfolio - May 11 2013]

Andre Choulika, Chairman and Chief Executive Officer of Cellectis Group, said, "This therapeutic focus strengthens the growth prospects of the Group, which is simultaneously pursuing other promising partnerships."

Cellectis Posts 2012 financial results [Published Individual.com - May 06 2013]

More Content

sort by: Date \| Relevance
Cellectis Secures 2 Patents for TAL-effector nu... [Published Individual.com - 4 hours ago]
Cell Therapy Catapult appoints CSO [Published Manufacturing Chemist - 22 hours ago]
Precision BioSciences wins patent infringement ... [Published Individual.com - May 17 2013]
ZFN Technology Advances Biopharmaceutical Manuf... [Published Pharmaceutical Technology - May 17 2013]
Cellectis: TAL-effector Nuclease: Issuance by t... [Published BioSpace - May 16 2013]
CELLECTIS: TAL-effector nuclease: Issuance by t... [Published 4 Traders - May 16 2013]
Nucléases effectrices TAL : L’USPTO1 a délivré ... [Published Business Wire Science: Science News - May 16 2013]
Cellectis: TAL-effector nuclease: Issuance by t... [Published Business Wire Science: Science News - May 16 2013]
Nucléases effectrices TAL : L’USPTO1 a délivré ... [Published Business Wire Education News - May 16 2013]
Cellectis: TAL-effector nuclease: Issuance by t... [Published Business Wire Education News - May 16 2013]
Nucléases effectrices TAL : L’USPTO1 a délivré ... [Published Business Wire Health News - May 16 2013]
Cellectis: TAL-effector nuclease: Issuance by t... [Published Business Wire Health News - May 16 2013]
Jury finds Cellectis meganuclease claims invali... [Published BioPortfolio - May 11 2013]
Jury finds Cellectis meganuclease claims invali... [Published Holman's Biotech IP Blog - May 10 2013]
Precision BioSciences Wins Patent Infringement ... [Published BioSpace - May 06 2013]
Durham's Precision Biosciences wins patent infr... [Published Triangle Business Journal - May 06 2013]
Precision BioSciences Wins Patent Infringement ... [Published NewsBlaze - May 06 2013]
Precision BioSciences Wins Patent Infringement ... [Published Business Wire - May 06 2013]
Precision BioSciences Wins Patent Infringement ... [Published Business Wire Health News - May 06 2013]
Cellectis Posts 2012 financial results [Published Individual.com - May 06 2013]
David Sourdive, Vice President of Corporate Dev... [Published NewsBlaze - May 02 2013]
David Sourdive, Vice Président du développement... [Published Business Wire Health News - May 02 2013]
David Sourdive, Vice President of Corporate Dev... [Published Business Wire Health News - May 02 2013]
Cellectis: 2012 financial results [Published Business Wire - Apr 29 2013]
Cellectis : résultats 2012 [Published Business Wire Science: Science News - Apr 29 2013]
Cellectis: 2012 financial results [Published Business Wire Science: Science News - Apr 29 2013]
Cellectis : résultats 2012 [Published Business Wire Health News - Apr 29 2013]
Cellectis: 2012 financial results [Published Business Wire Health News - Apr 29 2013]
Cellectis Bioresearch Rolls Out VizuCELL Cell L... [Published Zecco - Apr 22 2013]
Cellectis develops VizuCELL cell lines for biom... [Published PBR - News - Apr 18 2013]

Blogs

sort by: Date \| Relevance
Jury finds Cellectis meganuclease claims invali... [Published Holman's Biotech IP Blog - May 10 2013] As reported in an earlier post , on March 1, 2011, Cellectis sued Precision Biosciences in the District Court of Delaware [CIV-No.-11-173] for allegedly infringing US patent number 7,897,372, directed to "I-CreI Meganuclease Variants with Modified Specificity.” ...
Cellectis develops VizuCELL cell lines for biom... [Published PBR - News - Apr 18 2013] Cellectis bioresearch, a subsidiary of Cellectis, has developed VizuCELL cell lines for biomedical research and cell biology. ...
Cellectis, Stemgent to provide Genome-engineere... [Published PBR - News - Mar 08 2013] Cellectis bioresearch, a subsidiary of Cellectis Group, has signed a collaboration agreement with Stemgent to provide research services, which combine mRNA reprogramming technology and genome engineering. ...
Court Report [Published Patent Docs - Dec 11 2012] By Sherri Oslick -- About Court Report: Each week we will report briefly on recently filed biotech and pharma cases. Glycobiosciences, Inc. v. Anika Therapeutics, Inc. 1:12-cv-01963; filed November 25, 2012 in the District Court of the District of Columbia ...

Press Releases

sort by: Date \| Relevance
Nucléases effectrices TAL : L’USPTO1 a délivré ... [Published Business Wire Science: Science News - May 16 2013]
Cellectis: TAL-effector nuclease: Issuance by t... [Published Business Wire Science: Science News - May 16 2013]
Nucléases effectrices TAL : L’USPTO1 a délivré ... [Published Business Wire Education News - May 16 2013]
Cellectis: TAL-effector nuclease: Issuance by t... [Published Business Wire Education News - May 16 2013]
Nucléases effectrices TAL : L’USPTO1 a délivré ... [Published Business Wire Health News - May 16 2013]